FIGURE LEGENDS
FIGURE 1 . Hematoxylin-eosin staining of biopsied tumor
tissue (×400).
FIGURE 2. Magnetic resonance imaging (MRI) and18fluoro-2-deoxyglucose-positron emission tomography
(FDG-PET) showing the primary tumor before the initiation of
chemoradiotherapy. (A) MRI axial plane. (B) MRI sagittal
plane. (C) FDG-PET axial plane.
FIGURE 3. Computed tomography (CT) and18fluoro-2-deoxyglucose-positron emission tomography
(FDG-PET) showing multiple lymphadenopathy before the initiation of
chemoradiotherapy. (A–C) CT image showing enlarged lymph
nodes in the external iliac-, common iliac-, and para-aortic-lymph node
regions, respectively. (D–F) FDG-PET images corresponding to
A–C.
FIGURE 4. Schematic presentation of the treatment
protocol. CS, central shielding; CRP, serum C-reactive protein; fr,
fractions; G-CSF, serum granulocyte-colony stimulating factor; ICBT,
intracavitary brachytherapy; LN, lymph node; PALN, para-aortic lymph
node; Prophyl, prophylactic; RT, radiotherapy; WBC, white blood cell
count in the peripheral blood; WP, whole pelvis.
FIGURE 5. Magnetic resonance imaging (MRI) and computed
tomography (CT) after completion of chemoradiotherapy. (A, B)MRI of axial and sagittal planes, respectively, showing the uterine
cervix. (C–E) CT image showing the external iliac-, common
iliac-, and para-aortic-lymph node regions, respectively.
FIGURE 6. Computed tomography (CT) at 2 months after completion
of chemoradiotherapy. Metastatic tumors (arrows) in (A) the
left supraclavicular lymph node, (B) the liver, and (C,
D) the lung.
FIGURE 7. Kinetics of laboratory markers during the clinical
course. CRP, serum C-reactive protein; G-CSF, serum granulocyte-colony
stimulating factor; SCC, serum squamous cell carcinoma antigen; and WBC,
white blood cell count in the peripheral blood.